Preface. List of Contributors. Structure, Function, and Molecular Mechanisms of PPAR Action. 1. Peroxisome Proliferator Activated Receptor Alpha Coordinates Intermediary Metabolism During Fasting; S. Kersten, et al. 2. Design, Structure, and Function of Novel PPAR Ligands; T.M. Willson, et al. 3. Functions of PPAR Gamma in Macrophages and Atherosclerosis; A. Chawla, et al. Inflammation and Atherosclerosis. 4. PPARs and Atherogenesis: Mediators or Modulators of the Inflammatory Response in the Vessel Wall? N. Marx. 5. Role of PPARs in Inflammation, Atherosclerosis, and Thrombosis; A. Pilon, et al. 6. Effects of Thiazolidinediones on Vascular Reactivity and Endothelial Dysfunction; E.S. Horton, et al. PPARgamma and alpha as Therapeutic Targets in Diabetes. 7. Activation of Human PPAR Subtypes by Pioglitazone; H. Kimura, et al. 8. PPARgamma Mechanism of Action Studies; S. Kliewer. Animal Models to Study PPAR Functions. 9. The Role of PPARalpha in Fatty Acid Metabolism and Hepatocarcinogenesis: Studies with PPARalpha-Null Mice; F.J. Gonzalez. PPARalpha: From Basic Science to Clinical Applications. 10. PPARalpha, Lipoprotein Metabolism, Metabolic Disease, and Atherosclerosis; J.-C. Fruchart, et al. 11. PPARalpha and Atherosclerosis; J. Plutzky. 12. Regulation of CD36 by PPARgamma: Pro- or Anti-atherogenic? M. Febbraio, et al. Lipid and Lipoprotein Metabolism and Atherosclerosis. 13. Anti-inflammatory Properties of HighDensity Lipoproteins; P. Barter, et al. The Importance of Raising HDL: From PPARalpha to Clinical Implications. 14. The Low-HDL Syndrome: Epidemiology and Pathophysiology; G. Franceschini, et al. 15. Diabetes: A Growing CHD Epidemic; A. Hamsten, G. Steiner. Adipose Tissue, Obesity, and Diabetes. 16. Influence of PPARs on Muscle Lipid Metabolism and Insulin Resistance; E.W. Kraegen, et al. 17. PPARgamma in Adipogenesis and Insulin Resistance; S.R. Farmer, et al. PPARdelta: Function and Biology. 18. Pharmacology of a Selective Peroxisome Proliferator-Activated Receptor delta Agonist, GW 501516, in Obese Dyslipidemic Primates; W. Oliver, et al. PPARgamma: From Basic Science to Clinical Applications. 19. PPARgamma: A Regulator of Growth and Differentiation; S.R. Farmer, et al. 20. Peroxisome Proliferator Activator Receptor Gamma Agonists Inhibit the Development of Atherosclerosis in Low Density Lipoprotein Receptor-Deficient Male Mice; A.C. Li, C.K. Glass. 21. Are Thiazolidinediones Superior to Standard Therapy in the Treatment of Type 2 Diabetes? M.-R. Taskinen. Clinical Studies with PPAR Ligands. 22. PPARgamma Ligands and Intestinal Inflammation; A. Flanigan, et al. 23. Inflammatory Mechanisms in Alzheimer's Disease: beta-Amyloidd-Stimulated Proinflammatory Responses Are Blocked by PPARgamma Agonists; G. Landreth, et al. Index.
